Bibliography
- Achilladelis B, Antonakis N. The dynamics of technological innovation: the case of the pharmaceutical industry. Res Policy 2001;30(4):535-88
- European Federation of Pharmaceutical Industries and Associations (EFPIA). The pharmaceutical industry in figures. EFPIA, Brussels: 2008
- Adams CP, Brantner VV. Estimating the cost of new drug development: is it really 802 million dollars? Health Aff (Millwood) 2006;25(2):420-8
- DiMasi J, Hansen R, Grabowski H. The price of innovation: new estimates of drug development costs. J Health Econ 2003;22(2):151-85
- Levine DS. New Estimate of Drug Development Costs Pegs Total at $1.5 Billion. Available from: http://www.burrillreport.com/article-new_estimate_of_drug_development_ costs_pegs_ total_at_1_5_billion.html [Last accessed 14 May 2013]
- Cockburn I, Henderson R. Absorptive capacity, coauthoring behavior and the organisation of research in drug discovery. J Ind Econ 1998;46:157-82
- Quinn JB. Strategic outsourcing: leveraging knowledge capabilities. Sloan Manage Rev 1999;40(4):9-21
- Quinn JB. Outsourcing innovation: the new engine of growth. Sloan Manage Rev 2000;41(4):13-28
- Findlay SM. Outsourcing in pharma. Pharm Technol Eur 2007;19(5):13-14
- Van Arnum P. Outsourcing strategies of emerging pharma. Pharm Technol 2008;32(10):48-53
- Cassiman B, Veugelers R. Complementarity in the innovation strategy: internal research, external technology acquisition, and cooperation in research. IESE Business School Working Paper. PJB Publications; 2002. p. 457
- Veugelers R, Cassiman B. Make and buy in innovation strategies: evidence from belgian manufacturing firms. Res Policy 1999;28(1):63-80
- Arora A, Gambardella A. Complementarity and external linkages: the strategies of the large companies in biotechnology. J Ind Econ 1990;38:361-79
- Arora A, Gambardella A. Evaluating technological information and utilizing it: scientific knowledge, technological capability and external linkages in biotechnology. J Econ Behav Organisation 1994;24(1):91-114
- Veugelers R. Internal research expenditures and external technology sourcing. Res Policy 1997;26(3):303-16
- Maskell P, Pedersen T, Petersen B, Dick-Nielsen J. Learning paths to offshore outsourcing: from cost reduction to knowledge seeking. Industry Innov 2007;14(3):239-57
- Phlippen S, Vermeersch A. Complementarities and research boundaries of the firm: a project level study on pharmaceutical research. Tinbergen Institute Discussion Paper TI 2008-022/3 Pharmaceutical Strategies
- Festel G. Outsourcing chemical synthesis in the drug discovery process. Drug Discov Today 2011;16(5-6):237-43
- Festel G, Schicker A, Boutellier R. Performance improvement in pharmaceutical R&D through new outsourcing models. J Bus Chem 2010;7(2):89-96
- Falk M, Festel G. New ways to buy in chemistry. Scrip Mag 2002;58-9
- Festel G, Falk M, Hofmeier U. Leased competence: a new R&D model in outsourcing chemical synthesis. Chim Oggi Chem Today Outsourcing Compend 2003;21:1
- Festel G, Maas R, Bellof M. Getting access to new technologies – how chemical synthesis outsourcing can tweak the process of drug discovery. Chim Oggi Chem Today 2013;31(1):16-18